PMGC Holdings Inc. (ELAB) Stock Analysis & Investment Frameworks
PMGC Holdings Inc. (ELAB) stock analysis on Invetso. Review PMGC Holdings Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
PMGC Holdings Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
PMGC Holdings Inc. Key Financial Metrics
- Market Cap: $2.12M
- Revenue: $590084.00
- ROE: -118.11%
- ROIC: -39.73%
- Dividend Yield: N/A
About PMGC Holdings Inc.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
PMGC Holdings Inc. Investment Frameworks
Invetso analyzes PMGC Holdings Inc. (ELAB) across the following frameworks:
- PMGC Holdings Inc. 10Y Growth Potential
- PMGC Holdings Inc. Scenario Analysis
- PMGC Holdings Inc. Risks & Opportunities
- PMGC Holdings Inc. Economic Moat
- PMGC Holdings Inc. Business Model
- PMGC Holdings Inc. Management
- PMGC Holdings Inc. SWOT Analysis
- PMGC Holdings Inc. Porter's 5 Forces
- PMGC Holdings Inc. PESTLE Analysis
- PMGC Holdings Inc. ESG Analysis
